Skip to content

Evaluation of a Surgical Microscope Mounted Autorefractor When Used on Patients Lying in a Supine Position

Evaluation of a Surgical Microscope Mounted Autorefractor When Used on Patients Lying in a Supine Position

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01827748
Enrollment
20
Registered
2013-04-10
Start date
2013-03-31
Completion date
2013-03-31
Last updated
2013-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractive Error

Keywords

Autorefractor

Brief summary

The purpose of this study is to evaluate the accuracy and repeatability of an individually validated prototype autorefractor designed to be mounted on a surgical microscope.

Detailed description

The purpose of this study is to evaluate the accuracy and repeatability of an individually validated prototype autorefractor designed to be mounted on a surgical microscope. The goal is to evaluate 20 subjects with both the investigational instrument followed by a commercially available instrument.

Interventions

DEVICEIntraoperative Autorefractor IAR-1

This is an auto-refractor mounted on an operating microscope and used with the subject in a supine position

DEVICEHartmann-Shack Auto Refractor

Standard auto-refractor used with subject sitting upright in front of the instrument.

Sponsors

Adventus Technology
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Be at least 18 years of age as of the date of evaluation for the study. 2. Have: 1. Read the Informed Consent 2. been given an explanation of the Informed Consent 3. indicated understanding of the Informed Consent 4. signed the Informed Consent document. 3. Be willing and able to adhere to the instructions set forth in this protocol and able to participate in all scheduled evaluations. 4. Be in good general health, based on his/her knowledge. 5. Have a refractive error within the range of -10.00 to +30.00 Diopter sphere and up to 5.00 Diopter of refractive cylinder . 6. Have manifest refraction (BCVA) Snellen visual acuities (VA) equal to or better than 20/25 in each eye. -

Exclusion criteria

Subjects may not be enrolled in this study if any of the following apply: The subject is/has: 1. Allergy to Tropicamide or a previous adverse reaction to Tropicamide. 2. Poor personal hygiene as observed by the investigational site personnel. 3. Strabismus 4. Currently pregnant (to the best of the subject's knowledge) or is lactating. 5. Previous refractive surgery or current or previous orthokeratology treatment. 6. Aphakic or pseudophakic or has cataracts that interfere with visual acuity. 7. Ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome, lupus erythematosus, sclerodermia, keratoconus or type II diabetes. 8. The need for topical ocular medications or any medication which might interfere with the study evaluations. 9. The presence of clinically significant (grade 3 or 4) anterior segment abnormalities; inflammations such as iritis; or any infection of the eye, lids, or associated structures. 10. Slit lamp findings, including but not limited to: Pathological dry eye or associated dry eye symptoms with decreased tear levels and punctuate staining \> Grade 2 Pterygium Corneal scars within the visual axis Neovascularization or ghost vessels \> 1.0 mm in from the limbus Giant papillary conjunctivitis (GPC) of \> Grade 2 Anterior uveitis or iritis Seborrheic eczema, seborrheic conjunctivitis or blepharitis \-

Design outcomes

Primary

MeasureTime frameDescription
Assessment of the accuracy and repeatability of the Test device compared to the Control1 HourComparative auto refractor device measurement variation is defined as +/-0.25 Diopters

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026